Search for: "Par Pharmaceutical, Inc." Results 141 - 160 of 171
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: []   Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb)   General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
29 May 2009, 1:10 pm
The Federal Court recently issued its judgment in NPS Pharmaceuticals, Inc v. [read post]
26 May 2009, 6:27 am
Amylin Pharmaceuticals, Inc. arose out of a proxy contest in which two separate dissident stockholders [1] of Amylin, prevented from agreeing to form a unified minority slate by the Company's "poison pill," each proposed a slate of five nominees to the 12-member Amylin Board of Directors, thereby raising the possibility that a majority of the Board could be changed at the upcoming Annual Meeting despite each stockholder's seeking only minority representation. [read post]
8 May 2009, 8:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: []   Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs)   General Alicia Greenidge to step down as Director of IFPMA (Intellectual Property Watch) Flu crisis could lead to compulsory licences (Managing… [read post]
22 Apr 2009, 6:14 am
Citigroup has been hit with a $30 million auction-rate securities lawsuit filed by Braintree Laboratories, Inc., a specialty pharmaceutical company, reported Christine Caufield in an April 17, 2009 article posted on [read post]
19 Apr 2009, 7:13 pm
Par Pharmaceutical, Inc. v. [read post]
9 Apr 2009, 7:52 am
(IP Think Tank) Brazilian public-private partnerships in the pharma industry (IP tango) EU: ECJ to rule on reference on SPC Regulation interpretation from Lithuania in Kirin Amgen, Inc. v Lietuvos Respublikos valstybinis patentų biuras (The SPC Blog) India: Delhi High Court Dasatinib order: Is patent-drug regulatory linkage a necessity? [read post]
27 Mar 2009, 8:00 am
(Intellectual Property Watch) Two final thoughts on big pharma acquisitions (IP finance) Brazil: Patent term cutbacks in Brazil and pharmaceutical pipelines – IP Think Tank podcast 23 March 2009 (IP Think Tank) Brazil: Patent term cutbacks - Lobbying, intellectual property and superior courts (IP Think Tank) Brazil: Patent term extension (PTE) under TRIPs revisited and reviewed by Superior Court of Justice (IP tango) Denmark: Harmonisation in Denmark: Patents covering… [read post]
20 Mar 2009, 2:05 am
Sterling Drug, Inc., 416 F.2d 417, 426 (2d Cir. 1969).District of Columbia: McNeil Pharmaceutical v. [read post]
9 Mar 2009, 7:00 am
Skylight Studios275 Hudson Street, NYC7 pm - 10 pmPURCHASE TICKETS   Participating chefs Anne BurrellThe Food Network Anita LoAnnisa     Pichet OngP*ONG Suvir SaranDevi Lawrence Benenson Fiona and Stanley Druckenmiller Leslie Fay Pomerantz   Anita Jaffe   Bloomberg Davis Polk & Wardwell Jeffrey FashionCares 2009 May and Samuel Rudin Family Foundation Sonnenschein Nath &… [read post]
6 Mar 2009, 7:03 am
The complaint also names generic pharmaceutical companies Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories. [read post]
23 Dec 2008, 7:00 pm
It was withdrawn at Par Pharmaceuticals based on the Board of Directors' commitment to adopt the policy in 2009. [read post]
29 Oct 2008, 12:14 pm
" At least thee companies (Par Pharmaceutical Companies, MBIA and Blockbuster) have committed to providing an advisory vote in 2009; A number of companies where shareholders have approved say on pay have not implemented the practice. [read post]
18 Oct 2008, 8:19 am
In the Hatch-Waxman area, Pozen, Inc. announced Par Pharmaceutical Inc. has filed an application with the Food and Drug Administration [FDA] to make a generic version of Treximet, a migraine treatment Pozen developed with GlaxoSmithKline PLC, and shares of Pozen shed nearly 28 percent of their value on 17 Oct. 08 [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files opposition: Teva Pharma USA… [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
10 Mar 2008, 1:10 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993); General Electric Co. v. [read post]